Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: Global

Adamant Global Biotech

+ Add to Watchlist

ADGLBII:SW

3,882.70 CHF 0.000.00%

As of 10:56:00 ET on 04/23/2015.

Snapshot for Adamant Global Biotech (ADGLBII)

Year To Date: +15.64% 3-Month: +23.73% 3-Year: +47.15% 52-Week Range: 2,185.57 - 4,120.93
1-Month: -0.41% 1-Year: +69.91% 5-Year: - Beta vs SMI: 1.23

Mutual Fund Chart for ADGLBII

No chart data available.
  • ADGLBII:SW 3,882.70
  • 1M
  • 1Y
Interactive ADGLBII Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for ADGLBII

Adamant Global Biotech is an open-end fund incorporated in Switzerland. The objective of the Fund is to obtain long-term capital growth with active management. The Fund invests on a global basis in the shares of companies in the biotech sector.

Inception Date: 10-15-2010 Telephone: +41 800 850 050
Managers: JOHN MANIERI
Web Site: www.zkb.ch/fonds

Fundamentals for ADGLBII

NAV (on 2015-04-23) 3,882.70
Assets (M) (on 2015-04-23) 172.48
Fund Leveraged N
Minimum Investment 100,000.00
Minimum Subsequent Investment -

Dividends for ADGLBII

Dividend Type Omitted
Dividend Frequency Irreg
Last Dividend Net -
Dividend Yield (ttm) -

Fees & Expenses for ADGLBII

Front Load 1.20
Back Load 1.00
Current Mgmt Fee 1.20
Redemption Fee 1.00
12b1 Fee -
Expense Ratio 1.24

Top Fund Holdings for ADGLBII

Filing Date: 12/31/2014
Name Position Value % of Total
Celgene Corp 140,000 15,560,956 9.790%
Amgen Inc 95,000 15,036,458 9.460%
Biogen Inc 40,000 13,491,780 8.488%
Gilead Sciences Inc 140,000 13,112,603 8.250%
Alexion Pharmaceuticals Inc 57,000 10,479,738 6.593%
Vertex Pharmaceuticals Inc 73,000 8,617,330 5.421%
Regeneron Pharmaceuticals Inc 21,000 8,560,543 5.386%
Mylan NV 140,000 7,841,687 4.933%
Illumina Inc 40,000 7,336,317 4.616%
Medivation Inc 65,000 6,433,536 4.048%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil